Applications of 1-Ethyl-7-Chloro-6-Fluoro-1,4-Dihydro-4-Oxoquinoline-3-Carboxylic Acid in Industrial Manufacturing

As a vertically integrated manufacturer, we supply 1-Ethyl-7-Chloro-6-Fluoro-1,4-Dihydro-4-Oxoquinoline-3-Carboxylic Acid to regulated industries seeking quality consistency and technical support for their advanced chemical synthesis. Below are key downstream application scenarios and relevant operational parameters.

1. Pharmaceutical Active Pharmaceutical Ingredient (API) Synthesis: Fluoroquinolone Antibiotics

API manufacturers use our material as a direct precursor in fluoroquinolone antibiotic synthesis, including popular compounds such as levofloxacin and related derivatives. Production occurs under strictly regulated GMP plant conditions. Customers request a defined purity profile to enable predictable selectivity during cyclization and carboxylation stages. Competing on batch uniformity and low-level impurities secures process reliability.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• 21 CFR Part 210/211 US FDA cGMP for Drug Products
• European Pharmacopoeia (Ph. Eur.) monographs for APIs
• China Pharmacopoeia (ChP) requirements, including impurity profiles

Typical usage ratio

• Used at 1.0–1.2 molar equivalents relative to the desired final active, based on specific process route; the exact amount adjusts for yield, purity, and conversion efficiency during key condensation and cyclization steps.

Downstream process integration

• Feeds directly into condensation with amine intermediates under slightly basic aqueous or organic conditions; most clients deploy it early, preceding salt formation and final crystallization, to maintain chirality and yield.

Final product types

• Levofloxacin API (bulk)
• Ofloxacin API (bulk)
• Enoxacin API (bulk)
• Sparfloxacin API (bulk)

2. Veterinary Drug Intermediate Production

Veterinary pharmaceutical manufacturers employ this material to synthesize antibacterial actives for animal health. Production lines must control cross-contamination risk and comply with veterinary GMP rules. Stringent audits demand documented traceability from raw material sourcing. Our manufacturing documentation and analytical data support VICH and EMA veterinary dossier submissions.

Industry compliance standards

• Veterinary Drug GMP Standards (China; GB 18597-2001, as amended)
• EMA Guidelines on Good Manufacturing Practice — Veterinary Medicinal Products
• USP Veterinary compendial standards where required by market
• VICH GL9 (Guidelines on Impurities in New Veterinary Drug Substances)

Typical usage ratio

• Generally 0.95–1.1 molar equivalents, tuned according to different side-chain amine coupling partners, with close monitoring to minimize unreacted acid or impurities in final animal health API.

Downstream process integration

• Incorporates into amide bond formation as the acid partner, typically following activation to the acid chloride or in-situ esterification, before coupling with veterinary-specific N-heterocyclic amines.

Final product types

• Marbofloxacin veterinary API
• Danofloxacin veterinary API
• Enrofloxacin veterinary API
• Compound veterinary injectable and tablet products

3. Specialty Chemical Intermediate for Agrochemical Synthesis

Agrochemical formulators utilize our raw material as a synthetic intermediate when developing crop protection agents based on quinolone scaffolds. Performance criteria focus on low residual solvents and defined impurity fingerprints, with full batch traceability. In process, our acid undergoes further functionalization or ring modification under controlled conditions.

Industry compliance standards

• FAO/WHO Specifications for Plant Protection Products
• ISO 9001:2015 Quality Management Systems for chemical intermediates
• REACH (EC 1907/2006) registration as substance for use in European Union
• China National Standards for agrochemical ingredient purity and impurity limits (GB/T standards)

Typical usage ratio

• Ranges from 0.8–1.3 molar equivalents according to the target active’s synthesis route and downstream ring substitution plan, often fine-tuned during small-scale trial batches.

Downstream process integration

• Feeds as a building block into N-functionalization and halogenation steps; typically post-hydrogenation and pre-final product isolation during the formulation of active crop protection substances.

Final product types

• Agrochemical pre-formulations containing quinolone-based actives
• Herbicide intermediates
• Fungicide precursor blends
• Seed treatment concentrate products

4. Reference Standard and Analytical Control Material Supply

Quality control laboratories and pharmaceutical manufacturers require high-purity grades of this acid as a reference standard as well as a control substance for analytical method validation. Supplied with comprehensive certification documents, this grade supports development and ongoing operation of validated HPLC and GC assays, impurity quantification studies, and equipment calibration.

Industry compliance standards

• USP General Chapter <1225> Validation of Compendial Procedures
• Ph. Eur. 5.12. Reference Standards
• OECD Principles of Good Laboratory Practice (GLP)
• FDA Guidance for Industry: Analytical Procedures and Methods Validation

Typical usage ratio

• Aliquots prepared at 0.1–10 mg per sample run; concentration prepared per laboratory SOP or compendial validation requirement.

Downstream process integration

• Utilized as external or internal standard in HPLC/UPLC method development, calibration of chromatographic systems, and for comparison with commercial product impurities to assure batch consistency and regulatory compliance.

Final product types

• Certified reference standard vials
• Analytical QC kits
• Regulatory submission documentation
• Laboratory working solutions

5. Contract Research and Pharmaceutical Process Development

CROs and pharmaceutical R&D centers use this compound in early-stage route scouting, novel API evaluation, and process optimization campaigns. Our technical team provides support for documentation and troubleshooting synthesis or scale-up during route selection, with full disclosure of impurity data and stability profiles. Secure supply and full CMC documentation underpin project timelines and tech transfer.

Industry compliance standards

• ISO 9001:2015 and 21 CFR Part 58 (GLP) where required for regulated studies
• ICH M7 (R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities
• FDA and EMA expectations for Investigational Medicinal Product (IMP) manufacture
• Internal company-specific Safe Handling and Control protocols

Typical usage ratio

• Flexible use from 1–20 g scale (laboratory) up to multi-kilogram (pilot plant); experimental ratios optimized for each research batch, based on process mass intensity and step yield objectives.

Downstream process integration

• Integrated into medicinal chemistry synthetic steps; exposed to diverse acylation, amidation, or cyclization procedures upstream of active trial substance isolation or process scale-up.

Final product types

• Process development sample sets
• Lead compound candidates
• Investigational APIs
• Technology transfer working standards